Convergence Financial’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.43M Buy
5,670
+2,713
+92% +$584K 0.11% 97
2026
Q1
$643K Sell
2,957
-60
-2% -$13.3K 0.07% 133
2025
Q4
$689K Sell
3,017
-73
-2% -$16.6K 0.1% 103
2025
Q3
$715K Buy
3,090
+743
+32% +$151K 0.11% 101
2025
Q2
$436K Buy
2,347
+999
+74% +$186K 0.07% 125
2025
Q1
$282K Buy
+1,348
New +$262K 0.06% 140

Other funds holding ABBV

Convergence Financial's ABBV Position: Q2 2026 in Review

Convergence Financial increased its AbbVie (ABBV) stake by 92% in Q2 2026, buying an estimated $584K and bringing the position to 5,670 shares worth $1.43M. The position accounts for 0.11% of the portfolio, ranked #97.

Convergence Financial first reported a position in ABBV in Q1 2025 and has held it in 6 quarters since. 4,215 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Convergence Financial held 5,670 shares of AbbVie worth $1.43M as of Q2 2026.
  • Convergence Financial bought 2,713 AbbVie shares in Q2 2026, an estimated $584K.
  • AbbVie made up 0.11% of Convergence Financial's portfolio in Q2 2026, its #97 holding.
  • Convergence Financial first reported a position in AbbVie in Q1 2025 and has held it in 6 quarters since.
  • 4,215 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Convergence Financial's 13F filing for Q2 2026, filed 5 Aug 2026.